CA2589678A1 - Novel mch receptor antagonists - Google Patents

Novel mch receptor antagonists Download PDF

Info

Publication number
CA2589678A1
CA2589678A1 CA002589678A CA2589678A CA2589678A1 CA 2589678 A1 CA2589678 A1 CA 2589678A1 CA 002589678 A CA002589678 A CA 002589678A CA 2589678 A CA2589678 A CA 2589678A CA 2589678 A1 CA2589678 A1 CA 2589678A1
Authority
CA
Canada
Prior art keywords
methyl
amino
carboxylic acid
amide
biphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002589678A
Other languages
English (en)
French (fr)
Inventor
James Peter Beck
Brian David Wakefield
Frederic Laurent Cordier
Esteban Dominguez-Manzanares
Kevin Matthew Gardinier
Peter Michael Greenen
Kenneth Allen Savin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2589678A1 publication Critical patent/CA2589678A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CA002589678A 2004-12-17 2005-12-16 Novel mch receptor antagonists Abandoned CA2589678A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63711604P 2004-12-17 2004-12-17
US60/637,116 2004-12-17
PCT/US2005/045864 WO2006066173A2 (en) 2004-12-17 2005-12-16 Novel mch receptor antagonists

Publications (1)

Publication Number Publication Date
CA2589678A1 true CA2589678A1 (en) 2006-06-22

Family

ID=36481254

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002589678A Abandoned CA2589678A1 (en) 2004-12-17 2005-12-16 Novel mch receptor antagonists

Country Status (16)

Country Link
US (1) US7838543B2 (enExample)
EP (1) EP1828177B1 (enExample)
JP (1) JP4988591B2 (enExample)
CN (1) CN101072775A (enExample)
AT (1) ATE404555T1 (enExample)
AU (1) AU2005316313B2 (enExample)
BR (1) BRPI0517425A (enExample)
CA (1) CA2589678A1 (enExample)
DE (1) DE602005009021D1 (enExample)
DK (1) DK1828177T3 (enExample)
ES (1) ES2312048T3 (enExample)
MX (1) MX2007007226A (enExample)
PL (1) PL1828177T3 (enExample)
PT (1) PT1828177E (enExample)
SI (1) SI1828177T1 (enExample)
WO (1) WO2006066173A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006038680A1 (ja) 2004-10-01 2008-05-15 萬有製薬株式会社 ２−アリールカルボキサミド−含窒素複素環化合物
US7902356B2 (en) * 2004-12-17 2011-03-08 Eli Lilly And Company Thiazolopyridinone derivates as MCH receptor antagonists
US8518950B2 (en) 2005-01-25 2013-08-27 Synta Pharmaceuticals Corp. 2-amido pyrazines for inflammation and immune related uses
US8153813B2 (en) 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
US20110306597A1 (en) 2008-06-18 2011-12-15 James Michael Crawforth Nicotinamide Derivatives
WO2010010435A2 (en) * 2008-07-22 2010-01-28 Glenmark Pharmaceutical S.A. Fused oxazole and thiazole derivatives as trpms modulators
SA110310332B1 (ar) 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
MX2012015102A (es) 2010-07-06 2013-05-01 Astrazeneca Ab Agentes terapeuticos 976.
BR112013000925A2 (pt) 2010-07-15 2020-12-01 Bayer Intellectual Property Gmbh compostos heterocíclicos como pesticidas
TW201305152A (zh) * 2010-12-14 2013-02-01 Shionogi & Co 具有血管內皮脂肪酶抑制活性之苯并噻唑及吖苯并噻唑衍生物
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
JO3225B1 (ar) * 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
SMT202400142T1 (it) 2014-01-13 2024-05-14 Aurigene Oncology Ltd Enantiomeri (r) e (s) di n-(5-(3-idrossipirrolidin-1-il)-2-morfolinoossazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4-il)ossazolo-carbossammide in qualità di inibitori di irak4 per il trattamento di un cancro
MX374526B (es) 2015-06-22 2025-03-06 Actelion Pharmaceuticals Ltd Inhibidores de nadph oxidasa 4.
CN108024971A (zh) * 2015-07-15 2018-05-11 奥列基因发现技术有限公司 作为irak-4抑制剂的取代的氮杂化合物
CN120267671A (zh) * 2017-03-31 2025-07-08 奥锐金肿瘤有限公司 用于治疗血液病的化合物和组合物
MX2020003666A (es) 2017-10-31 2020-08-03 Curis Inc Compuestos y composiciones para el tratamiento de trastornos hematologicos.
CN109485620A (zh) * 2018-12-26 2019-03-19 安徽工大化工科技有限公司 一种2-甲氧基-6-甲氧基苯并噻唑的制备方法
AU2020274645A1 (en) * 2019-05-14 2021-12-16 Metabomed Ltd ACSS2 inhibitors and methods of use thereof
US12178821B2 (en) 2021-04-08 2024-12-31 Curis, Inc. Combination therapies for the treatment of cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756496A (en) 1994-05-28 1998-05-26 Smithkline Beecham P.L.C. Amide derivatives having 5HT1D-antagonist activity
EP0971878B1 (en) 1997-02-27 2008-03-26 Takeda Pharmaceutical Company Limited Amine compounds, their production and use as amyloid-beta production inhibitors
US7115750B1 (en) 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
WO2001057008A1 (en) 2000-02-07 2001-08-09 Abbott Gesellschaft Mit Beschrankter Haftung & Company Kommanditgesellschaft 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors
ATE479429T1 (de) * 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
CA2408913A1 (en) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
CA2428191A1 (en) * 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
DE10139126A1 (de) * 2001-08-09 2003-02-20 Ciba Sc Pfersee Gmbh Zusammensetzungen aus Polysiloxanen, Fluorpolymeren und Extendern
DE10139416A1 (de) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CA2468544A1 (en) * 2001-12-10 2003-06-19 Amgen Inc. Vanilloid receptor ligands
WO2004011440A1 (ja) * 2002-07-30 2004-02-05 Banyu Pharmaceutical Co., Ltd. ベンズイミダゾール誘導体を有効成分とするメラニン凝集ホルモン受容体拮抗剤
CA2509202A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Fused heterocyclic derivatives as ppar modulators
KR100925307B1 (ko) * 2005-03-09 2009-11-04 에프. 호프만-라 로슈 아게 항당뇨성 화합물로서 벤조티아졸, 티아졸로피리딘,벤조옥사졸 및 옥사졸로피리딘 유도체

Also Published As

Publication number Publication date
US7838543B2 (en) 2010-11-23
AU2005316313B2 (en) 2011-09-29
WO2006066173A2 (en) 2006-06-22
MX2007007226A (es) 2007-08-21
DE602005009021D1 (de) 2008-09-25
SI1828177T1 (sl) 2009-02-28
US20090170913A1 (en) 2009-07-02
CN101072775A (zh) 2007-11-14
PT1828177E (pt) 2008-10-28
JP4988591B2 (ja) 2012-08-01
WO2006066173A3 (en) 2006-07-27
PL1828177T3 (pl) 2009-01-30
EP1828177B1 (en) 2008-08-13
ATE404555T1 (de) 2008-08-15
ES2312048T3 (es) 2009-02-16
EP1828177A2 (en) 2007-09-05
AU2005316313A1 (en) 2006-06-22
DK1828177T3 (da) 2008-11-17
BRPI0517425A (pt) 2008-10-07
JP2008524249A (ja) 2008-07-10

Similar Documents

Publication Publication Date Title
AU2005316313B2 (en) Novel MCH receptor antagonists
CA2484233A1 (en) Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
ES2289336T3 (es) Derivados heteroarilicos condensados para su uso como inhibidores de quinasa p38 en el tratamiento de, entre otras, artritis reumatoide.
JP6971999B2 (ja) ピペラジン誘導体の酸付加塩
CA2375008C (en) Phenoxypropylamine compounds
US20080153810A1 (en) Indazole derivatives useful as melanin concentrating receptor ligands
CN105120860B (zh) 组蛋白脱乙酰酶抑制剂
AU2007275212B2 (en) Morpholinyl and pyrrolidinyl analogs
BR112018002304B1 (pt) Compostos de derivado de 1,3,4-oxadiazol como inibidor de histona desacetilase 6 e a composição farmacêutica que compreende os mesmos
NZ566862A (en) Diarylamine-containing compounds and compositions, and their use as modulators of C-kit receptors
CN1317003A (zh) 具有抗肿瘤活性的嘧啶衍生物
JP2003532730A (ja) 細胞増殖抑制剤として有用な１，１−ジオキソイソチアゾリジンを持つインダゾール
RS57332B1 (sr) Heterociklični amidi kao inhibitori kinaze
RS64423B1 (sr) Inhibitori lizin specifične demetilaze-1
US20140256740A1 (en) Compounds and methods
WO2009090548A2 (en) 3-azabicyclo [3.1.0] hexane derivatives as vanilloid receptor ligands
JP6975860B2 (ja) Ｍｙｓｔファミリーのｋａｔ阻害剤として作用する縮合［１，２，４］チアジアジン誘導体
MX2014010668A (es) Acetamidas heterociclicas sustituidas como agonistas del receptor opioide kappa (kor).
US20100222396A1 (en) 4-aryl-butane-1,3-diamides
JP2007522142A (ja) Ｉｋｋ３に対して活性を有するベンゾイミダゾール置換チオフェン誘導体
CA2542220A1 (en) Novel mch receptor antagonists
EA008801B1 (ru) Получение арилалкилкарбаматных производных и их применение в терапии
EP1648448A1 (en) Chemical compounds
US20050239841A1 (en) New compounds
US20120015957A1 (en) Piperazinyl derivatives useful as modulators of the neuropeptide y2 receptor

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131217